Zeynep Melekoglu Ellik
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Zeynep Melekoglu Ellik has a total of 162 co-authors. Here are the top co-authors by number of shared publications:
- Ramazan Idilman
Department of Gastroenterology, Ankara University School of Medicine, Ankara, Turkey
14 shared publications - Hale Gokcan
Department of Gastroenterology, Ankara University School of Medicine, Ankara, Turkiye
8 shared publications - Atilla Halil Elhan
Department of Biostatistics, Ankara University Medical School, Ankara, Turkey
6 shared publications - Yasemin Hatice Balaban
Division of Gastroenterology, Department of Internal Medical Sciences, Hacettepe University School of Medicine, Ankara, Turkiye
5 shared publications - Berna Savaş
Department of Pathology, Ankara University School of Medicine, Ankara, Turkiye
4 shared publications - Haydar Adanir
Department of Gastroenterology, Akdeniz University Faculty of Medicine, Antalya, Türkiye
4 shared publications
Latest Publications
- 13 April 2026
- Published by Wolters Kluwer Health in Liver Transplantation
- Vol. 32 (10) , 1413-1423
Comparison of MELD, MELD-Na, and MELD 3.0 scoring systems for transplant prioritization in the Turkish population: A multicenter study
The Model for End-stage Liver Disease Sodium (MELD-Na) score predicts mortality in liver transplant candidates. MELD 3.0 has been proposed as an improved model for estimating mortality risk. This study evaluated MELD 3.0’s predictive accuracy for short-term mortality among Turkish liver transplant candidates and compared its performance with MELD and MELD-Na scores. Patients listed both for deceased donor transplants and living donor transplants were analyzed in the study. The discriminative abilities of MELD, MELD-Na, and MELD 3.0 scores were assessed using the area under the receiver operating characteristic curve (AUROC). Comparisons between AUROC values used the DeLong test. The most predictive cutoff for MELD 3.0 was determined using the Youden index. Transplant-free survival was analyzed using the Kaplan–Meier method, with survival curves compared using the log-rank test. A total of 1689 patients were included in this nationwide, multicenter study. Hepatitis B was the leading cause of cirrhosis (29%, n=491), followed by metabolic dysfunction–associated steatohepatitis (20%, n=335). For 3-month mortality, MELD 3.0 had the highest AUROC (0.753), followed by MELD-Na (0.747) and MELD (0.725). The most predictive cutoff values were 18 for MELD and 21 for MELD-Na and MELD 3.0. Both MELD-Na and MELD 3.0 outperformed MELD ( p p =0.17). MELD 3.0 and MELD-Na demonstrated superior performance to MELD in predicting 3-month mortality among Turkish liver transplant candidates, though their predictive accuracy was comparable. Further refinements are needed to enhance MELD 3.0’s clinical utility.
- 13 April 2026
- Published by Wolters Kluwer Health in Liver Transplantation
- Vol. 32 (10) , 1413-1423
Comparison of MELD, MELD-Na, and MELD 3.0 scoring systems for transplant prioritization in the Turkish population: A multicenter study
The Model for End-stage Liver Disease Sodium (MELD-Na) score predicts mortality in liver transplant candidates. MELD 3.0 has been proposed as an improved model for estimating mortality risk. This study evaluated MELD 3.0’s predictive accuracy for short-term mortality among Turkish liver transplant candidates and compared its performance with MELD and MELD-Na scores. Patients listed both for deceased donor transplants and living donor transplants were analyzed in the study. The discriminative abilities of MELD, MELD-Na, and MELD 3.0 scores were assessed using the area under the receiver operating characteristic curve (AUROC). Comparisons between AUROC values used the DeLong test. The most predictive cutoff for MELD 3.0 was determined using the Youden index. Transplant-free survival was analyzed using the Kaplan–Meier method, with survival curves compared using the log-rank test. A total of 1689 patients were included in this nationwide, multicenter study. Hepatitis B was the leading cause of cirrhosis (29%, n=491), followed by metabolic dysfunction–associated steatohepatitis (20%, n=335). For 3-month mortality, MELD 3.0 had the highest AUROC (0.753), followed by MELD-Na (0.747) and MELD (0.725). The most predictive cutoff values were 18 for MELD and 21 for MELD-Na and MELD 3.0. Both MELD-Na and MELD 3.0 outperformed MELD ( p p =0.17). MELD 3.0 and MELD-Na demonstrated superior performance to MELD in predicting 3-month mortality among Turkish liver transplant candidates, though their predictive accuracy was comparable. Further refinements are needed to enhance MELD 3.0’s clinical utility.
- Open Access
- 20 February 2026
- Published by AVES YAYINCILIK A.Ş. in Turkish Journal of Gastroenterology
- Vol. 37 (4) , 510-523
De Novo Malignancies after Liver Transplantation: A Multicenter Cohort Study of Incidence, Timing, and Outcomes*
Background/Aims: De novo malignancies are an important long-term complication following liver transplantation (LT), driven bychronic immunosuppression and extended post-transplant survival. Understanding patterns by tumor type, timing, and patient characteristics is essential for optimized surveillance. This study aimed to evaluate the clinical characteristics and temporal trends of de novoneoplasms in LT recipients.Materials and Methods: A total of 6943 adult LT recipients from 16 Turkish centers were evaluated between 1999 and 2023). Two hundred eight patients with 220 histologically confirmed de novo malignancies (excluding hepatocellular carcinoma) were included. Patientswho died within 30 days or developed cancer within 90 days post-LT were excluded. Incidence and mortality rates were assessed acrosspost-transplant intervals.Results: Non-skin solid (53.2%), dermatologic (28.6%), and hematologic (18.2%) cancers were predominant. Most malignancies (76.8%)occurred within 10 years post-LT. Early-onset (<10 years) malignancies were more common in living donor recipients (62.7%, P = .001)and associated with higher mortality (39.6% vs. 11.8%, P < .001). Recipients ≤60 years exhibited a higher incidence of hematologiccancers (23.9% vs. 12.6%, P = .03) and increased mortality (39.4% vs. 27.0%, P = .05). In subgroup analysis, tacrolimus use was stronglyassociated with cutaneous squamous cell carcinoma (P = .004). Peak incidence occurred 2-10 years post-LT (≈13-14 per 1000 recipients), with non-skin solid tumors being the most frequent.Conclusion: De novo malignancies remain a significant long-term risk after LT, with outcomes influenced by tumor type, age, immunosuppression, and timing of onset. Risk-adapted surveillance and tailored oncologic management, particularly dermatologic screeningin tacrolimus-treated patients and enhanced surveillance during the 2-10 year post-transplant period are recommended to improvelong-term survival.Cite this article as: Danış N, Döngelli H, Ünek T, et al. De novo malignancies after liver transplantation: A multicenter cohort studyof incidence, timing, and outcomes. Turk J Gastroenterol. Published online February 20, 2026. doi:10.5152/tjg.2026.25748.
- 20 February 2026
- Published by AVES YAYINCILIK A.Ş. in Turkish Journal of Gastroenterology
- Vol. 37 (4) , 510-523
Open AccessDe Novo Malignancies after Liver Transplantation: A Multicenter Cohort Study of Incidence, Timing, and Outcomes*
Background/Aims: De novo malignancies are an important long-term complication following liver transplantation (LT), driven bychronic immunosuppression and extended post-transplant survival. Understanding patterns by tumor type, timing, and patient characteristics is essential for optimized surveillance. This study aimed to evaluate the clinical characteristics and temporal trends of de novoneoplasms in LT recipients.Materials and Methods: A total of 6943 adult LT recipients from 16 Turkish centers were evaluated between 1999 and 2023). Two hundred eight patients with 220 histologically confirmed de novo malignancies (excluding hepatocellular carcinoma) were included. Patientswho died within 30 days or developed cancer within 90 days post-LT were excluded. Incidence and mortality rates were assessed acrosspost-transplant intervals.Results: Non-skin solid (53.2%), dermatologic (28.6%), and hematologic (18.2%) cancers were predominant. Most malignancies (76.8%)occurred within 10 years post-LT. Early-onset (<10 years) malignancies were more common in living donor recipients (62.7%, P = .001)and associated with higher mortality (39.6% vs. 11.8%, P < .001). Recipients ≤60 years exhibited a higher incidence of hematologiccancers (23.9% vs. 12.6%, P = .03) and increased mortality (39.4% vs. 27.0%, P = .05). In subgroup analysis, tacrolimus use was stronglyassociated with cutaneous squamous cell carcinoma (P = .004). Peak incidence occurred 2-10 years post-LT (≈13-14 per 1000 recipients), with non-skin solid tumors being the most frequent.Conclusion: De novo malignancies remain a significant long-term risk after LT, with outcomes influenced by tumor type, age, immunosuppression, and timing of onset. Risk-adapted surveillance and tailored oncologic management, particularly dermatologic screeningin tacrolimus-treated patients and enhanced surveillance during the 2-10 year post-transplant period are recommended to improvelong-term survival.Cite this article as: Danış N, Döngelli H, Ünek T, et al. De novo malignancies after liver transplantation: A multicenter cohort studyof incidence, timing, and outcomes. Turk J Gastroenterol. Published online February 20, 2026. doi:10.5152/tjg.2026.25748.
- 1 January 2026
- Published by Kare Publishing in Hepatology Forum
- Vol. 7 (4) , 337-344
Hepatitis B surface antigen seroclearance after nucleos(t) ide analogue discontinuation in non-cirrhotic patients with chronic hepatitis B
Background and Aim: This study aimed to evaluate the clinical outcomes following the discontinuation of nucleos(t)ide analogue (NA) treatment in hepatitis B e antigen (HBeAg)-negative patients with chronic hepatitis B (CHB). Materials and Methods: This single-center retrospective cohort study included 146 non-cirrhotic patients with CHB who achieved long-term viral suppression under NA treatment. Seventy-three patients discontinued NA treatment, while a historical age- and sex-matched control group consisted of 73 patients who continued NA treatment. Results: Hepatitis B surface antigen (HBsAg) seroclearance occurred in eight patients (11%) in the treatment-discontinuation group, while none was observed in the treatment-contin-ued group (p = 0.004). The cumulative probability of HBsAg loss was 16.9% at month 120 after NA discontinuation. Firth-penalized Cox regression analysis identified younger age (
- 1 January 2026
- Published by Kare Publishing in Hepatology Forum
- Vol. 7 (4) , 337-344
Hepatitis B surface antigen seroclearance after nucleos(t) ide analogue discontinuation in non-cirrhotic patients with chronic hepatitis B
Background and Aim: This study aimed to evaluate the clinical outcomes following the discontinuation of nucleos(t)ide analogue (NA) treatment in hepatitis B e antigen (HBeAg)-negative patients with chronic hepatitis B (CHB). Materials and Methods: This single-center retrospective cohort study included 146 non-cirrhotic patients with CHB who achieved long-term viral suppression under NA treatment. Seventy-three patients discontinued NA treatment, while a historical age- and sex-matched control group consisted of 73 patients who continued NA treatment. Results: Hepatitis B surface antigen (HBsAg) seroclearance occurred in eight patients (11%) in the treatment-discontinuation group, while none was observed in the treatment-contin-ued group (p = 0.004). The cumulative probability of HBsAg loss was 16.9% at month 120 after NA discontinuation. Firth-penalized Cox regression analysis identified younger age (
- Open Access
- 1 January 2026
- Published by Kare Publishing in Hepatology Forum
- Vol. 7 (1) , 26-31
Efficacy and tolerability of tenofovir alafenamide fumarate prophylaxis in HBV-infected individuals receiving chemo/immunosuppressive therapy
Background and Aim: This study aimed to determine the efficacy and safety of tenofovir alafenamide fumarate (TAF) prophylaxis in hepatitis B virus (HBV)-infected or HBV-experienced individuals with benign and malignant diseases receiving chemo/immunosuppressive or biological modifier therapy. Materials and Methods: This is a multicenter, observational study in which data from 13 centers were reviewed and entered into a standardized electronic case report form. Results: A total of 158 individuals who received TAF prophylaxis were included in the analysis. Before starting the prophylaxis, 51 individuals were hepatitis B surface antigen positive, while 107 were HBV-experi-enced. Thirty patients had detectable HBV DNA levels. Twelve of them had abnormal serum alanine aminotransferase levels. Forty patients were switched to TAF. Solid tumors (34%) were the most common primary disease types. The median follow-up period was 17.2 months. From baseline to the end of the follow-up period, none of the patients had clinical, biochemical, or serological evidence of HBV reactivation under TAF prophylaxis. The virological response rate was 87%. HBV suppression was well maintained after switching in the 40 patients who were switched to TAF treatment. All patients maintained their chemo/immunosuppressive therapy without interruption. TAF prophylaxis was well tolerated. No drug discontinuation due to adverse effects was observed. No HBV-related morbidity or mortality was observed during the TAF prophylaxis. No significant differences were found in the glomerular filtration rate change or hypophosphatemia during TAF pro-phylaxis, but the serum triglyceride levels were significantly increased (p=0.019). Conclusion: TAF prophylaxis is effective, safe, and tolerable in preventing chemo/immunosuppressive or biological modifier-induced HBV reactivation in HBV-infected or HBV-experienced individuals.
- 1 January 2026
- Published by Kare Publishing in Hepatology Forum
- Vol. 7 (1) , 26-31
Open AccessEfficacy and tolerability of tenofovir alafenamide fumarate prophylaxis in HBV-infected individuals receiving chemo/immunosuppressive therapy
Background and Aim: This study aimed to determine the efficacy and safety of tenofovir alafenamide fumarate (TAF) prophylaxis in hepatitis B virus (HBV)-infected or HBV-experienced individuals with benign and malignant diseases receiving chemo/immunosuppressive or biological modifier therapy. Materials and Methods: This is a multicenter, observational study in which data from 13 centers were reviewed and entered into a standardized electronic case report form. Results: A total of 158 individuals who received TAF prophylaxis were included in the analysis. Before starting the prophylaxis, 51 individuals were hepatitis B surface antigen positive, while 107 were HBV-experi-enced. Thirty patients had detectable HBV DNA levels. Twelve of them had abnormal serum alanine aminotransferase levels. Forty patients were switched to TAF. Solid tumors (34%) were the most common primary disease types. The median follow-up period was 17.2 months. From baseline to the end of the follow-up period, none of the patients had clinical, biochemical, or serological evidence of HBV reactivation under TAF prophylaxis. The virological response rate was 87%. HBV suppression was well maintained after switching in the 40 patients who were switched to TAF treatment. All patients maintained their chemo/immunosuppressive therapy without interruption. TAF prophylaxis was well tolerated. No drug discontinuation due to adverse effects was observed. No HBV-related morbidity or mortality was observed during the TAF prophylaxis. No significant differences were found in the glomerular filtration rate change or hypophosphatemia during TAF pro-phylaxis, but the serum triglyceride levels were significantly increased (p=0.019). Conclusion: TAF prophylaxis is effective, safe, and tolerable in preventing chemo/immunosuppressive or biological modifier-induced HBV reactivation in HBV-infected or HBV-experienced individuals.
- Open Access
- 1 January 2026
- Published by Kare Publishing in Hepatology Forum
- Vol. 7 (1) , 14-20
Hepatic steatosis is associated with HBsAg seroclearance in patients with chronic hepatitis B virus infection but it is also associated with disease progression
Background and Aim: The present study aimed to determine the effect of hepatic steatosis, as detected by liver biopsy, on Hepatitis B surface antigen (HbsAg) seroclearance and disease progression in patients infected with hepatitis B virus (HBV). Materials and Methods: Patients with chronic HBV infection and chronic hepatitis B (CHB) from an existing cohort of HBV-infected patients were enrolled. Results: This study included 296 patients: 186 with chronic HBV in-fection and 110 with CHB. Patients with chronic HBV infection were older (p=0.006), and exhibited a higher prevalence of wild-type mutants (p
- 1 January 2026
- Published by Kare Publishing in Hepatology Forum
- Vol. 7 (1) , 14-20
Open AccessHepatic steatosis is associated with HBsAg seroclearance in patients with chronic hepatitis B virus infection but it is also associated with disease progression
Background and Aim: The present study aimed to determine the effect of hepatic steatosis, as detected by liver biopsy, on Hepatitis B surface antigen (HbsAg) seroclearance and disease progression in patients infected with hepatitis B virus (HBV). Materials and Methods: Patients with chronic HBV infection and chronic hepatitis B (CHB) from an existing cohort of HBV-infected patients were enrolled. Results: This study included 296 patients: 186 with chronic HBV in-fection and 110 with CHB. Patients with chronic HBV infection were older (p=0.006), and exhibited a higher prevalence of wild-type mutants (p
- Open Access
- 1 January 2025
- Published by Kare Publishing in Hepatology Forum
- Vol. 6 (4) , 141-145
The impact of long-term potent antiviral therapy on the natural course of disease in patients with hepatitis B virusrelated cirrhosis
Background and Aim: The present study compared the long-term efficacy of weak and potent antiviral treatments in patients with hepatitis B virus (HBV)-related cirrhosis. Materials and Methods: A total of 120 patients with HBV-related cirrho-sis were enrolled. The primary outcome measure was viral suppression. A secondary outcome measure was to determine the development of decom-pensation or hepatocellular carcinoma (HCC). Results: The virological response (VR) was significantly better in pa-tients treated with potent antiviral agents than in those treated with weaker antiviral agents over time (p
- 1 January 2025
- Published by Kare Publishing in Hepatology Forum
- Vol. 6 (4) , 141-145
Open AccessThe impact of long-term potent antiviral therapy on the natural course of disease in patients with hepatitis B virusrelated cirrhosis
Background and Aim: The present study compared the long-term efficacy of weak and potent antiviral treatments in patients with hepatitis B virus (HBV)-related cirrhosis. Materials and Methods: A total of 120 patients with HBV-related cirrho-sis were enrolled. The primary outcome measure was viral suppression. A secondary outcome measure was to determine the development of decom-pensation or hepatocellular carcinoma (HCC). Results: The virological response (VR) was significantly better in pa-tients treated with potent antiviral agents than in those treated with weaker antiviral agents over time (p
- Open Access
- 15 October 2024
- Published by AVES YAYINCILIK A.Ş. in Turkish Journal of Gastroenterology
- Vol. 35 (10) , 772-777
Changing Trends in the Etiology of Cirrhosis in Türkiye: A Multicenter Nationwide Study
Background/Aims: The aim of our study was to investigate the underlying causes behind the etiology of cirrhosis in Türkiye. Materials and Methods: The study was comprised of patients with cirrhosis located in the gastroenterology clinics of 28 centers in Türkiye between January 2000 and June 2021. Results: The study group consisted of 4953 cirrhotic patients (median age: 62.2 years, male / female: 58% / 42%). Among the patients, 39% of the patients were compensated, and 61% were decompensated. Furthermore, 47.5% had Child-Pugh class A, 38% had ChildPugh class B, and 14.5% had Child-Pugh class C. The most frequent complaints were abdominal bloating (28%). Ascites (54.2%) was the most common manifestation of decompensation. The median Child-Pugh and MELD-Na scores were 7.0 and 10.0, respectively. The most common cause of cirrhosis was chronic viral hepatitis (43%), followed by cryptogenic cirrhosis (CC) (19%), metabolic dysfunction-associated steatotic liver disease (MASLD)-related cirrhosis (13%), and alcohol-related cirrhosis (11%). Among the 950 patients with CC, 416 had metabolic abnormalities. If these 416 CC patients with metabolic abnormalities were categorized as having MASLDrelated cirrhosis, the proportion of MASLD-related cirrhosis increased to 21%. Thirteen percent of the patients were diagnosed with HCC, while 4% had extrahepatic malignancy. Female breast cancer (18%) and colorectal cancer (18%) were the most frequent extrahepatic malignancies. Conclusion: Viral hepatitis remains the main cause of cirrhosis in Türkiye. However, its prevalence seems to be declining, whereas the prevalence of steatotic liver disease-related cirrhosis is increasing. Cite this article as: Üçbilek E, Yıldırım AE, Ellik Z, et al. Changing trends in the etiology of cirrhosis in Türkiye: A multicenter nationwide study. Turk J Gastroenterol. 2024;35(10):772-777.
- 15 October 2024
- Published by AVES YAYINCILIK A.Ş. in Turkish Journal of Gastroenterology
- Vol. 35 (10) , 772-777
Open AccessChanging Trends in the Etiology of Cirrhosis in Türkiye: A Multicenter Nationwide Study
Background/Aims: The aim of our study was to investigate the underlying causes behind the etiology of cirrhosis in Türkiye. Materials and Methods: The study was comprised of patients with cirrhosis located in the gastroenterology clinics of 28 centers in Türkiye between January 2000 and June 2021. Results: The study group consisted of 4953 cirrhotic patients (median age: 62.2 years, male / female: 58% / 42%). Among the patients, 39% of the patients were compensated, and 61% were decompensated. Furthermore, 47.5% had Child-Pugh class A, 38% had ChildPugh class B, and 14.5% had Child-Pugh class C. The most frequent complaints were abdominal bloating (28%). Ascites (54.2%) was the most common manifestation of decompensation. The median Child-Pugh and MELD-Na scores were 7.0 and 10.0, respectively. The most common cause of cirrhosis was chronic viral hepatitis (43%), followed by cryptogenic cirrhosis (CC) (19%), metabolic dysfunction-associated steatotic liver disease (MASLD)-related cirrhosis (13%), and alcohol-related cirrhosis (11%). Among the 950 patients with CC, 416 had metabolic abnormalities. If these 416 CC patients with metabolic abnormalities were categorized as having MASLDrelated cirrhosis, the proportion of MASLD-related cirrhosis increased to 21%. Thirteen percent of the patients were diagnosed with HCC, while 4% had extrahepatic malignancy. Female breast cancer (18%) and colorectal cancer (18%) were the most frequent extrahepatic malignancies. Conclusion: Viral hepatitis remains the main cause of cirrhosis in Türkiye. However, its prevalence seems to be declining, whereas the prevalence of steatotic liver disease-related cirrhosis is increasing. Cite this article as: Üçbilek E, Yıldırım AE, Ellik Z, et al. Changing trends in the etiology of cirrhosis in Türkiye: A multicenter nationwide study. Turk J Gastroenterol. 2024;35(10):772-777.
- Open Access
- 15 August 2024
- Published by AVES YAYINCILIK A.Ş. in Turkish Journal of Gastroenterology
- Vol. 35 (8) , 634-642
Liver Stiffness and Steatosis Measurements with iLivTouch and FibroScan: A Comparative Study
Background/Aims: The presence of liver fibrosis is the most important indicator of progression to cirrhosis. Noninvasive measurement of liver stiffness is crucial for detecting fibrosis. Vibration-controlled transient elastography is one of the most useful methods for this purpose. We aimed to compare the liver stiffness and steatosis measurements with iLivTouch© and the FibroScan© elastography devices Materials and Methods: Two hundred thirty-seven consecutive adult patients with chronic hepatitis were included in the study. The liver stiffness and steatosis were measured with iLivTouch and FibroScan on the same day. Thirty-one patients had liver biopsies on the same day with elastography procedures. The diagnostic performances of iLivTouch and FibroScan were compared to aspartate aminotransferase to platelet ratio index (APRI), Fibrosis-4 (FIB-4), and nonalcoholic fatty liver disease fibrosis score (NFS). Results: The liver stiffness measurements obtained using iLivTouch and FibroScan had median value of 10.3 (ranging from 2.9 to 46.3) and 7.2 (ranging from 2.5 to 75), respectively. The mean steatosis measurements using ultrasound attenuation parameter with iLivTouch were 245.51 ± 45.79, while the mean controlled attenuation parameter measurements using FibroScan were 259.37 ± 75.0. In subgroup analysis, the AUC of iLivTouch on detecting signiicant fibrosis [0.83, (P = .002)] was minimally higher than other noninvasive methods [0.82 for NFS (P = .003), 0.80 for FibroScan (P = .006), 0.68 for FIB-4 (P = .089), and 0.53 for APRI (P = .76)]. Conclusion: The stiffness and steatosis measurements with iLivTouch and FibroScan were not similar. The accuracy of iLivTouch in detecting significant and advanced fibrosis was minimally higher. Large clinical trials are necessary to support these findings. Cite this article as: Özercan M, Melekoğlu Ellik Z, Parmaksız A, Gümüşsoy M, Duman S, Örmeci N. Liver stiffness and steatosis measurements with iLivTouch and FibroScan: A comparative study. Turk J Gastroenterol. 2024;35(8):634-642.
- 15 August 2024
- Published by AVES YAYINCILIK A.Ş. in Turkish Journal of Gastroenterology
- Vol. 35 (8) , 634-642
Open AccessLiver Stiffness and Steatosis Measurements with iLivTouch and FibroScan: A Comparative Study
Background/Aims: The presence of liver fibrosis is the most important indicator of progression to cirrhosis. Noninvasive measurement of liver stiffness is crucial for detecting fibrosis. Vibration-controlled transient elastography is one of the most useful methods for this purpose. We aimed to compare the liver stiffness and steatosis measurements with iLivTouch© and the FibroScan© elastography devices Materials and Methods: Two hundred thirty-seven consecutive adult patients with chronic hepatitis were included in the study. The liver stiffness and steatosis were measured with iLivTouch and FibroScan on the same day. Thirty-one patients had liver biopsies on the same day with elastography procedures. The diagnostic performances of iLivTouch and FibroScan were compared to aspartate aminotransferase to platelet ratio index (APRI), Fibrosis-4 (FIB-4), and nonalcoholic fatty liver disease fibrosis score (NFS). Results: The liver stiffness measurements obtained using iLivTouch and FibroScan had median value of 10.3 (ranging from 2.9 to 46.3) and 7.2 (ranging from 2.5 to 75), respectively. The mean steatosis measurements using ultrasound attenuation parameter with iLivTouch were 245.51 ± 45.79, while the mean controlled attenuation parameter measurements using FibroScan were 259.37 ± 75.0. In subgroup analysis, the AUC of iLivTouch on detecting signiicant fibrosis [0.83, (P = .002)] was minimally higher than other noninvasive methods [0.82 for NFS (P = .003), 0.80 for FibroScan (P = .006), 0.68 for FIB-4 (P = .089), and 0.53 for APRI (P = .76)]. Conclusion: The stiffness and steatosis measurements with iLivTouch and FibroScan were not similar. The accuracy of iLivTouch in detecting significant and advanced fibrosis was minimally higher. Large clinical trials are necessary to support these findings. Cite this article as: Özercan M, Melekoğlu Ellik Z, Parmaksız A, Gümüşsoy M, Duman S, Örmeci N. Liver stiffness and steatosis measurements with iLivTouch and FibroScan: A comparative study. Turk J Gastroenterol. 2024;35(8):634-642.
- Open Access
- 13 May 2024
- Published by Galenos Yayinevi in Diagnostic and Interventional Radiology
- Vol. 30 (6) , 351-356
Assessing hepatic steatosis by magnetic resonance in potential living liver donors
To determine the accuracy of magnetic resonance imaging-proton density fat fraction (MRI-PDFF) measurements for detecting liver fat content in potential living liver donors and to compare these results using liver biopsy findings. A total of 139 living liver donors (men/women: 83/56) who underwent MRI between January 2017 and September 2021 were included in this analysis retrospectively. The PDFFs were measured using both MR spectroscopy (MRS) and chemical shift-based MRI (CS-MRI) for each donor in a blinded manner. Significant positive correlations were found between liver biopsy and MRS-PDFF and CS-MRI PDFF in terms of hepatic steatosis detection [r = 0.701, 95% confidence interval (CI): 0.604-0.798, r = 0.654, 95% CI: 0.544-0.765, P < 0.001, respectively). A weak level correlation was observed between liver biopsy, MRI methods, and vibration-controlled transient elastography attenuation parameters in 42 available donors. Based on receiver operating characteristic (ROC) analysis, MRS-PDFF and CS-MRI PDFF significantly distinguished >5% of histopathologically detected hepatic steatosis with an area under the ROC curve (AUC) of 0.837 ± 0.036 (P < 0.001, 95% CI: 0.766-0.907) and 0.810 ± 0.036 (P < 0.001, 95% CI: 0.739-0.881), respectively. The negative predictive values (NPVs) of MRS-PDFF and CS-MRI PDFF were 88.3% and 81.3%, respectively. In terms of distinguishing between clinically significant hepatic steatosis (≥10% on histopathology), the AUC of MRS-PDFF and CS-MRI were 0.871 ± 0.034 (P < 0.001 95% CI: 0.804-0.937) and 0.855 ± 0.036 (P < 0.001, 95% CI: 0.784-0.925), respectively. The NPVs of MRS-PDFF and CS-MRI were 99% and 92%, respectively. The methods of MRS-PDFF and CS-MRI PDFF provide a non-invasive and accurate approach for assessing hepatic steatosis in potential living liver donor candidates. These MRI PDFF techniques present a promising clinical advantage in the preoperative evaluation of living liver donors by eliminating the requirement for invasive procedures like liver biopsy.
- 13 May 2024
- Published by Galenos Yayinevi in Diagnostic and Interventional Radiology
- Vol. 30 (6) , 351-356
Open AccessAssessing hepatic steatosis by magnetic resonance in potential living liver donors
To determine the accuracy of magnetic resonance imaging-proton density fat fraction (MRI-PDFF) measurements for detecting liver fat content in potential living liver donors and to compare these results using liver biopsy findings. A total of 139 living liver donors (men/women: 83/56) who underwent MRI between January 2017 and September 2021 were included in this analysis retrospectively. The PDFFs were measured using both MR spectroscopy (MRS) and chemical shift-based MRI (CS-MRI) for each donor in a blinded manner. Significant positive correlations were found between liver biopsy and MRS-PDFF and CS-MRI PDFF in terms of hepatic steatosis detection [r = 0.701, 95% confidence interval (CI): 0.604-0.798, r = 0.654, 95% CI: 0.544-0.765, P < 0.001, respectively). A weak level correlation was observed between liver biopsy, MRI methods, and vibration-controlled transient elastography attenuation parameters in 42 available donors. Based on receiver operating characteristic (ROC) analysis, MRS-PDFF and CS-MRI PDFF significantly distinguished >5% of histopathologically detected hepatic steatosis with an area under the ROC curve (AUC) of 0.837 ± 0.036 (P < 0.001, 95% CI: 0.766-0.907) and 0.810 ± 0.036 (P < 0.001, 95% CI: 0.739-0.881), respectively. The negative predictive values (NPVs) of MRS-PDFF and CS-MRI PDFF were 88.3% and 81.3%, respectively. In terms of distinguishing between clinically significant hepatic steatosis (≥10% on histopathology), the AUC of MRS-PDFF and CS-MRI were 0.871 ± 0.034 (P < 0.001 95% CI: 0.804-0.937) and 0.855 ± 0.036 (P < 0.001, 95% CI: 0.784-0.925), respectively. The NPVs of MRS-PDFF and CS-MRI were 99% and 92%, respectively. The methods of MRS-PDFF and CS-MRI PDFF provide a non-invasive and accurate approach for assessing hepatic steatosis in potential living liver donor candidates. These MRI PDFF techniques present a promising clinical advantage in the preoperative evaluation of living liver donors by eliminating the requirement for invasive procedures like liver biopsy.